Ferrlecit - Experience. Confidence.

Ferrlecit^® is an iron replacement product for the treatment of iron deficiency anemia in adult patients and in patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy.

For U.S. Healthcare Professionals Only

Print
E-mail
Text:AAA

sanofi aventis

Home > E-mail to Colleague

E-mail a colleague

Want to share this page with a U.S.-based colleague? Please provide the information below. If you would like to send your message to multiple recipients, separate each e-mail address with a semicolon (;).

* Required field

Your name *
Your e-mail address *
Colleague's e-mail address *

Send a copy to myself.

E-mail address information will be used only for the purposes of e-mailing this page and will not be stored or used for any other purpose.

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferrlecit (sodium ferric gluconate) in post marketing experience. Patients may present with shock, clinically significant hypotension, loss of consciousness, or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferrlecit administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferrlecit when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.

Ferrlecit is contraindicated in patients with known hypersensitivity to Ferrlecit.
Ferrlecit may cause clinically significant hypotension. Administration of Ferrlecit may augment hypotension caused by dialysis and usually resolves within one to two hours. Monitor patients for sign and symptoms of hypotension during and following administration.
Do not administer to patients with evidence of iron overload.
Ferrlecit contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with serious adverse events and death in pediatric patients. Caution should be exercised when Ferrlecit is administered to a pregnant or nursing woman.
The most commonly reported adverse reactions (≥10%):
- In adult patients were nausea, vomiting and/or diarrhea, injection site reaction, hypotension, cramps, hypertension, dizziness, dyspnea, chest pain, leg cramps and pain.
- In patients 6 to 15 years of age the most common adverse reactions (≥10%) were hypotension, headache, hypertension, tachycardia and vomiting.

For more information on Ferrlecit, please see full Prescribing Information.

For more information on Ferrlecit,
please see full Prescribing Information

© 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY. All rights reserved.
Legal Disclaimer Information and Privacy Policy
Questions or comments? Click here to contact us.
This site intended for use by U.S. Healthcare Professionals.
US.FER.12.09.001 Last Update: January 2013